Metformin Response Effectiveness

SLC22A1 codes for OCT1 — the transporter that moves metformin from blood into liver cells, where it does its work. The drug can’t lower hepatic glucose output if it can’t get into the hepatocytes. OCT1 efficiency is the rate-limiting step for metformin’s primary mechanism.

Carriers of common SLC22A1 reduced-function variants are associated with lower hepatic metformin concentrations and reduced glucose-lowering effect. The same variants are associated with higher gut-side concentrations — and a higher rate of GI side effects (nausea, diarrhea) at standard doses. The two patterns often appear together.

Extended-release formulations reduce GI exposure and side effects. Co-administered medications that compete for OCT1 (some PPIs, certain antibiotics) reduce metformin’s effective dose further. Vitamin B12 monitoring matters long-term — metformin chronically lowers B12 absorption regardless of variant.

If metformin "didn’t work" or "wasn’t tolerated" the first time, that’s not necessarily a failure of the drug. It’s often a failure of dose and form against an OCT1 variant pattern — and the conversation with the prescribing clinician changes when that pattern is on the table.